XTL Biopharmaceuticals Ltd.
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$3.75
FAIR PRICE
$3.39
MARGIN
$0.36
P/E Ratio
N/A
Div. Yield
N/A
ROE
-25.5%
Average
Market Cap
$1M
Small-cap
NOW AVAILABLE
Get notified when XTLB's fair price changes
Push notifications when XTLB's valuation shifts. Available on iOS and Android.
FPI RATING
Attractive valuation, but weak profitability margins and below-average fundamental quality.
Analytical data, not an investment recommendation. Updated daily.
How we calculate this ↗MARGIN OF SAFETY
A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.
SAFETY MARGIN
20%
Below fair value
ENTRY LEVEL
$2.71
Fair price × 0.80
DISTANCE
27.7%
Price to entry level
At the current price of $3.75, XTLB trades 27.7% above the conservative entry level of $2.71. This entry level represents a 20% margin of safety below the calculated fair price of $3.39 — a buffer that accounts for estimation uncertainty in the valuation model.
Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗
VALUATION HISTORY
Loading chart data...
P/E RATIO HISTORY
Loading chart data...
METHODOLOGY
How we calculate XTLB's fair price
XTL Biopharmaceuticals Ltd.'s fair price of $3.39 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $3.75, XTLB trades 9.6% above its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting XTLB's risk profile.
RELATIVE · 30%
Comparing XTLB's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for XTLB, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate XTLB's fair value with your own inputs.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for XTLB.
Explore on BuliosFAQ
What is the fair price of XTLB?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for XTL Biopharmaceuticals Ltd. is $3.39. At the current market price of $3.75, XTLB trades 9.6% above its calculated fair value.
Is XTLB overvalued or undervalued?+
XTL Biopharmaceuticals Ltd. is currently fair based on our valuation model. The stock trades at $3.75, which is 9.6% above the fair price of $3.39.
What is the margin of safety for XTLB?+
With a 20% margin of safety applied to the fair price of $3.39, the conservative entry level for XTLB is $2.71. At the current market price of $3.75, the stock trades 27.7% above this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.
How often is XTLB's fair price updated?+
We update fair price calculations for XTLB daily after market close. The current fair price of $3.39 incorporates the latest market data and sector multiples.
What factors affect XTLB's fair price calculation?+
XTLB's fair price of $3.39 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of -25.5%.
Is XTLB a good buy right now?+
At $3.75, XTLB trades 9.6% above our fair value estimate of $3.39. The stock is currently fair. ROE stands at -25.5% (average). Fair Price Index provides valuation data — always do your own research before investing.
Does XTLB pay dividends?+
XTLB does not currently pay a dividend.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.